BioCentury
ARTICLE | Clinical News

BeiGene's zanubrutinib leads to 84% ORR in Chinese pivotal trial for MCL

July 6, 2018 4:44 PM UTC

BeiGene Ltd. (NASDAQ:BGNE) said zanubrutinib (BGB-3111) led to an overall response rate (ORR) of 84%, including a complete response rate of 59%, in a Chinese pivotal Phase II trial in 86 patients with relapsed or refractory mantle cell lymphoma (MCL). Median duration of response has not been reached at a median follow-up of 8.3 months. Data were presented at the European Hematology Association meeting in Stockholm...